NKTR Nektar Therapeutics

12.14
+0.12  (1%)
Previous Close 12.02
Open 12.05
Price To book 0.00
Market Cap 1.86B
Shares 152,835,000
Volume 967,112
Short Ratio 6.80
Av. Daily Volume 1,533,530

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 1H 2017.
Cipro DPI
Bronchiectasis
Approved November 16 2015
ADYNOVATE
Hemophilia A
Approved Sept 16 2014
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 3 topline data mid March 2015 did not reach primary endpoint
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Data due March 2017.
NKTR-181
Lower back pain
Phase 1/2 ongoing. Initial data due 1H 2017.
NKTR-214
Solid tumors - cancer
Phase 3 data due June/July 2017.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 data released December 12, 2016 - primary endpoint not met.
Fovista
Wet-AMD

Latest News

  1. Benzinga's Option Alert Recap From January 23
  2. NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
  3. Nektar Therapeutics – Value Analysis (NASDAQ:NKTR) : January 6, 2017
  4. Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
  5. Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : January 5, 2017
  6. ETFs with exposure to Nektar Therapeutics : December 27, 2016
  7. Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings
  8. ETFs with exposure to Nektar Therapeutics : December 16, 2016
  9. These small-cap stocks are expected to rise at least 31% in 2017
  10. ETFs with exposure to Nektar Therapeutics : December 6, 2016
  11. Is The New York Times Co (NYT) A Good Stock To Buy?
  12. ETFs with exposure to Nektar Therapeutics : November 14, 2016
  13. Nektar Therapeutics to Present at Jefferies 2016 Global Healthcare Conference in London
  14. NEKTAR THERAPEUTICS Financials
  15. Nektar Therapeutics :NKTR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
  16. Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
  17. NEKTAR THERAPEUTICS Files SEC form 8-K, Other Events
  18. Nektar (NKTR) Stock Up on Narrower-than-Expected Q3 Loss
  19. Coverage initiated on Nektar Therapeutics by Aegis Capital
  20. Cormorant Asset Management’s Bets on Alder Biopharmaceuticals Inc (ALDR) and Other Healthcare Stocks Show Strong Returns

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17530023
  2. 8-K - Current report 17520875
  3. CT ORDER - Confidential treatment order 162032015
  4. 8-K - Current report 161982826
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161973440
  6. 8-K - Current report 161972131
  7. 8-K - Current report 161942969
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161942940
  9. 424B5 - Prospectus [Rule 424(b)(5)] 161939453
  10. 8-K - Current report 161939440